Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Pediatric Hematology/Oncology|December 11, 2013
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experienceDaniel A Morgenstern, Darren Hargrave, Lynley V Marshall, et al.
JCO Precision Oncology|September 19, 2025
Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing ConsortiumAntonio Juan Ribelles, Arthur Felix, Nuria Benavent, et al.
Human Mutation|December 1, 2015
MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient ChildSusanne A Gatz, Daniela Salles, Eva-Maria Jacobsen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMARTBirgit Geoerger, Francisco Bautista, Nicolas André, et al.
Molecular Oncology|December 1, 2021
FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomasChristopher I Milton, Joanna Selfe, Ewa Aladowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2023
Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART TrialSusanne A Gatz, Anne C Harttrampf, Caroline Brard, et al.
Cancers|October 16, 2025
Childhood, Adolescent and Young Adult Poor-Prognosis RhabdomyosarcomaAjla T Wasti, Gianni Bisogno, Raquel Hladun, et al.
Blood|October 23, 2013
SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCIDCatharina Schuetz, Benedicte Neven, Christopher C Dvorak, et al.
Pageof 4